Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights

Overview

Journal Dement Neurocogn Disord

Date 2024 Nov 8

PMID 39512701

Authors

Hyemin Jang

Daeun Shin

Yeshin Kim

Ko Woon Kim

Juyoun Lee

Jun Pyo Kim

Hee Jin Kim

Soo Hyun Cho

Si Eun Kim

Duk L Na

Sang Won Seo

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Dementia, particularly Alzheimer's disease, is a significant global health concern, with early diagnosis and treatment development being critical goals. While numerous cohorts have advanced dementia research, there is a lack of comprehensive data on ethnic differences, particularly for the Korean population. The Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) aims to establish a large-scale, hospital-based dementia cohort to address this gap, with a focus on understanding disease progression, developing early diagnostics, and supporting treatment advancements specific to the Korean population.

Methods: K-ROAD comprises multiple prospective cohorts. Participants underwent clinical evaluations, neuroimaging, and biomarker analysis, with data collected on a range of clinical and genomic markers.

Results: As of December 2023, K-ROAD has recruited over 5,800 participants, including individuals across the Alzheimer's clinical syndrome, subcortical vascular cognitive impairment, and frontotemporal dementia spectra. Preliminary findings highlight significant ethnic differences in amyloid positivity, cognitive decline, and biomarker profiles, compared to Western cohorts.

Conclusions: The K-ROAD cohort offers a unique and critical resource for dementia research, providing insights into ethnic-specific disease characteristics and biomarker profiles. These findings will contribute to the development of personalized diagnostic and therapeutic approaches to dementia, enhancing global understanding of the disease.

Citing Articles

Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.

Kim S, Shin D, Ham H, Kim Y, Gu Y, Kim H JAMA Netw Open. 2025; 8(3):e250096.

PMID: 40042844 PMC: 11883494. DOI: 10.1001/jamanetworkopen.2025.0096.

Temporal Dynamics and Biological Variability of Alzheimer Biomarkers.

Yun J, Shin D, Lee E, Kim J, Ham H, Gu Y JAMA Neurol. 2025; .

PMID: 39960728 PMC: 11833660. DOI: 10.1001/jamaneurol.2024.5263.

Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics.

Jang H, Shin D, Yoo H, Zetterberg H, Blennow K, Gonzalez-Ortiz F Alzheimers Dement. 2025; 21(2):e14526.

PMID: 39907189 PMC: 11848384. DOI: 10.1002/alz.14526.

Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors.

Lee E, Kang S, Shin D, Kim Y, Zetterberg H, Blennow K Alzheimers Dement. 2024; 21(1):e14368.

PMID: 39535473 PMC: 11782842. DOI: 10.1002/alz.14368.

References

OBryant S, Waring S, Cullum C, Hall J, Lacritz L, Massman P . Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008; 65(8):1091-5. PMC: 3409562. DOI: 10.1001/archneur.65.8.1091. View

Klunk W, Koeppe R, Price J, Benzinger T, Devous Sr M, Jagust W . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2014; 11(1):1-15.e1-4. PMC: 4300247. DOI: 10.1016/j.jalz.2014.07.003. View

Sled J, Zijdenbos A, Evans A . A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998; 17(1):87-97. DOI: 10.1109/42.668698. View

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

Zammit M, Tudorascu D, Laymon C, Hartley S, Zaman S, Ances B . PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. Neuroimage. 2021; 228:117728. PMC: 7953340. DOI: 10.1016/j.neuroimage.2021.117728. View

Jack Jr C, Wiste H, Weigand S, Knopman D, Mielke M, Vemuri P . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015; 138(Pt 12):3747-59. PMC: 4655341. DOI: 10.1093/brain/awv283. View

Kang S, Kim M, Jang H, Kwon H, Lee H, Kim H . Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum. Neurology. 2021; 96(17):e2201-e2211. DOI: 10.1212/WNL.0000000000011833. View

Jang H, Kim H, Choe Y, Kim S, Park S, Kim Y . The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. J Alzheimers Dis. 2020; 78(2):573-585. DOI: 10.3233/JAD-200680. View

Jang H, Kim H, Park S, Park Y, Choe Y, Cho H . Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. Eur J Nucl Med Mol Imaging. 2019; 47(2):292-303. DOI: 10.1007/s00259-019-04498-y. View

10.

Kang S, Park Y, Lee D, Kim J, Chin J, Ahn Y . The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dement Neurocogn Disord. 2019; 18(3):77-95. PMC: 6819670. DOI: 10.12779/dnd.2019.18.3.77. View

11.

Kim K, Woo S, Kim S, Jang H, Kim Y, Cho S . Disease progression modeling of Alzheimer's disease according to education level. Sci Rep. 2020; 10(1):16808. PMC: 7544693. DOI: 10.1038/s41598-020-73911-6. View

12.

Ahn H, Chin J, Park A, Lee B, Suh M, Seo S . Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010; 25(7):1071-6. PMC: 2890886. DOI: 10.3346/jkms.2010.25.7.1071. View

13.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

14.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

15.

Chun M, Park C, Kim J, Jeong J, Jang H, Kim K . Prediction of conversion to dementia using interpretable machine learning in patients with amnestic mild cognitive impairment. Front Aging Neurosci. 2022; 14:898940. PMC: 9389270. DOI: 10.3389/fnagi.2022.898940. View

16.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

17.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

18.

Wardlaw J, Smith E, Biessels G, Cordonnier C, Fazekas F, Frayne R . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12(8):822-38. PMC: 3714437. DOI: 10.1016/S1474-4422(13)70124-8. View

19.

Zijdenbos A, Forghani R, Evans A . Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2003; 21(10):1280-91. DOI: 10.1109/TMI.2002.806283. View

20.

Kim J, Kim J, Jang H, Kim J, Kang S, Kim J . Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Sci Rep. 2021; 11(1):6954. PMC: 7997887. DOI: 10.1038/s41598-021-86114-4. View